TREVENA, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 41 rows in 2014. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2014-12-16: Reporting owner Phillips Anne M.; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2014-09-17: Reporting owner Koppel Adam; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2014-07-01: Reporting owner Yanni Barbara; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2014-07-01: Reporting owner McHugh Julie; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2014-12-16 | Phillips Anne M. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,741 17,741 owned after | $4.50 exercise price | 2014-12-17 | |
| 2014-09-17 | Koppel Adam Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,741 17,741 owned after | $5.66 exercise price | 2014-09-19 | |
| 2014-07-01 | Yanni Barbara Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,741 17,741 owned after | $5.83 exercise price | 2014-07-01 | |
| 2014-07-01 | McHugh Julie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,741 17,741 owned after | $5.83 exercise price | 2014-07-01 | |
| 2014-05-20 holding as of filing | Cuca Roberto Officer (Sr. VP and CFO) | 3/A | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $7.44 exercise price | 2014-05-20 | ||
| 2014-05-14 | CHAMPSI FARAH Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,870 8,870 owned after | $4.78 exercise price | 2014-05-15 | |
| 2014-05-14 | DOUGHERTY MICHAEL R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,870 8,870 owned after | $4.78 exercise price | 2014-05-15 | |
| 2014-05-14 | MCGUIRE TERRANCE Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,870 8,870 owned after | $4.78 exercise price | 2014-05-15 | |
| 2014-05-14 | MOULDER LEON O JR Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,870 8,870 owned after | $4.78 exercise price | 2014-05-15 | |
| 2014-05-14 | Nader Francois Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,870 8,870 owned after | $4.78 exercise price | 2014-05-15 | |
| 2014-05-14 | Solomon David F Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,870 8,870 owned after | $4.78 exercise price | 2014-05-15 | |
| 2014-05-14 | Limongelli John M Officer (Sr. VP,General Counsel & Secy) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $4.78 exercise price | 2014-05-15 | |
| 2014-05-14 | Nunn Jason Raleigh Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,870 8,870 owned after | $4.78 exercise price | 2014-05-15 | |
| 2014-04-23 | GOWEN MAXINE Director, Officer (President & CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −124,477 106,329 owned after | $0.68 exercise price | 2014-05-15 | |
| 2014-03-31 | Prachar Robert Officer (Sr. VP, Corp. Strategy) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $7.86 exercise price | 2014-04-02 | |
| 2014-02-20 | Deegan Rosamond Officer (Sr VP, Bus Dev & Operations) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +60,000 60,000 owned after | $7.40 exercise price | 2014-03-11 | |
| 2014-02-20 | Soergel David Officer (Sr. VP, Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +55,000 55,000 owned after | $7.40 exercise price | 2014-03-11 | |
| 2014-02-20 | Cuca Roberto Officer (Sr. VP and CFO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $7.40 exercise price | 2014-03-11 | |
| 2014-02-20 | Lark Michael W. Officer (Sr. VP, Research & CSO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $7.40 exercise price | 2014-03-11 | |
| 2014-02-20 | GOWEN MAXINE Director, Officer (President & CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +175,000 175,000 owned after | $7.40 exercise price | 2014-03-11 | |
| 2014-01-30 | Deegan Rosamond Officer (Sr VP, Bus Dev & Operations) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $7.00 exercise price | 2014-01-31 | |
| 2014-01-30 | Nader Francois Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,741 17,741 owned after | $7.00 exercise price | 2014-01-31 | |
| 2014-01-30 holding as of filing | DOUGHERTY MICHAEL R Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $7.44 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | MOULDER LEON O JR Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.68 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | Deegan Rosamond Officer (Sr VP, Bus Dev & Operations) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $0.06 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | Deegan Rosamond Officer (Sr VP, Bus Dev & Operations) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $0.68 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | Deegan Rosamond Officer (Sr VP, Bus Dev & Operations) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $0.68 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | Deegan Rosamond Officer (Sr VP, Bus Dev & Operations) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $2.23 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | Lark Michael W. Officer (Sr. VP, Research & CSO) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $2.23 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | Lark Michael W. Officer (Sr. VP, Research & CSO) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $0.68 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | Lark Michael W. Officer (Sr. VP, Research & CSO) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $0.68 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | Soergel David Officer (Sr. VP, Clinical Development) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $2.23 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | Soergel David Officer (Sr. VP, Clinical Development) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $0.68 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | Soergel David Officer (Sr. VP, Clinical Development) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $0.68 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | Soergel David Officer (Sr. VP, Clinical Development) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $0.68 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | Soergel David Officer (Sr. VP, Clinical Development) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $0.06 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | Cuca Roberto Officer (Sr. VP and CFO) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $7.44 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | GOWEN MAXINE Director, Officer (President & CEO) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $0.68 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | GOWEN MAXINE Director, Officer (President & CEO) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $0.68 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | GOWEN MAXINE Director, Officer (President & CEO) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $2.23 exercise price | 2014-01-30 | ||
| 2014-01-30 holding as of filing | GOWEN MAXINE Director, Officer (President & CEO) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $7.44 exercise price | 2014-01-30 |